Twist Bioscience Expects Q4 2024 Revenues Of $82M-$83M Versus Prior Guidance Of $77M-$80M And Consensus Of $79.602M
Portfolio Pulse from Benzinga Newsdesk
Twist Bioscience has updated its Q4 2024 revenue guidance to $82M-$83M, surpassing both its prior guidance of $77M-$80M and the consensus estimate of $79.602M. The company also expects a gross margin of approximately 44% and an adjusted EBITDA loss of $20 million.
August 02, 2024 | 11:37 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Twist Bioscience has raised its Q4 2024 revenue guidance to $82M-$83M, exceeding both its prior guidance and the consensus estimate. The company also expects a gross margin of 44% and an adjusted EBITDA loss of $20 million.
The upward revision in revenue guidance and the expected gross margin improvement are positive indicators for Twist Bioscience. These factors are likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100